The production of Interleukin 6 (IL6) was studied during experimental cerebral malaria (ECM) induced by Plasmodium berghei ANKA (PbA) infection . IL6 is present in the serum of mice with ECM, the highest concentrations being observed in mice with full-blown neurological syndrome. High IL6 levels were also observed, however, in the absence of pathology in nonlethal malaria infection. These data suggest that IL6 is produced in large amounts during malaria infection, but does not play a major role in the pathogenesis of ECM . A modulation of IL6 production in ECM was achieved by in vivo treatment with other anticytokine antibodies: antibodies to interferon (IFN -'y) or to tumor necrosis factor (TNF) abolished the rise of 11,6, while anti-IL3 and anti-granulocyte/macrophage colony-stimulating factor antibodies only partially prevented this rise, suggesting that the two cytokines IFN--y and TNF are important intermediates in IL6 production . Passive immunization against IL6 did not prevent ECM, but significantly reduced serum IgG levels in malaria-infected mice. Thus, by its effects on B cells, IL6 may be involved in hypergammaglobulinemia and immune-complex diseases, e.g., glomerulonephritis observed during malaria infection .
Experimental cerebral malaria (ECM) is a hyperacute lethal syndrome reproducing some features of human cerebral malaria (1), the most severe complication and cause of death of Plasmodium falciparum infection (2) . We have shown that (a) ECM is strictly dependent upon the presence of T cells (3) and is accompanied by a marked expansion of monocyte/macrophage pool in lymphoid organs (4) ; (b) overproduction of TNF plays a`central pathogenic role (5) ; and (c) a cascade of T cell-derived cytokines is required for this TNF overproduction to occur (4, 6) .
IL6 is a cytokine with pleiotropic effects that can be produced by a variety of cell types (7, 8) , including monocytes, T cells, and endothelial cells (9) , which are central to the lesion of CM (5) . Also, it has been shown that the synthesis and release of 11,6 can be induced by TNF (10, 11) . Therefore, we have analyzed the possible contribution of IL6 to the pathogenesis of ECM .
Materials and Methods
Mice. Female CBA/Ca mice, originally obtained from Bomholtgard (Ry, Denmark) and bred in our laboratory, were 6-8 wk old at the time of infection .
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Infection. P. berghei ANKA (PbA) infection was initiated as described (3) . 17 XNL Plasmodium yoelii was from Dr. J .H .L. Playfair (Middlesex Hospital, London, UK) . 11, 6 Assay. 11,6 activity was assayed by using the 7TD1 bioassay (7) revealed by MTT (12) . The 7TD1 hybridoma cell line was kindly donated by Dr. J . Van Snick, Ludwig Institute, Brussels, Belgium .
Anticytokine Antibodies. Rabbit anti-mouse TNF (5), antimouse 11,3, and anti-mouse granulocyte/macrophage (GM)-CSF (4) antisera (produced in our laboratory), and rat anti-mouse IFN-y (F3) IgG2a mAb (13) were injected in malaria-infected animals following protocols previously shown to be protective against ECM (4-6) . 6114, a rat IgG1 anti-murine IL6 mAb (500 NU/ml on 1 U of murine rIL6, one neutralizing unit (NU) being defined as the reciprocal ofthe dilution of the antibody leading to a 50% inhibition of I1,6-induced growth of 7TD1 cells), was kindly donated by Dr. J . Van Snick (14) and used as ascitic fluid .
Immunoglobulin Assays. Serum IgG and IgM levels were measured using ELISA, according to a procedure derived from that o£ Izui et al . (15) .
Antimalarial Antibodies. Serum anti-P. berghei antibodies were measured by ELISA and by slide immunofluorescence as previously described (3) .
Statistical Analysis. Means were compared using the nonparametric Mann Whitney test .
Results
Kinetics of IL6 during Malaria Infection . Series of mice that are genetically susceptible to CM (CBA/Ca) were inoculated with PbAinfected erythrocytes, and bled daily from day 4 to day 7 . Serum IIr6 remained in the range of noninfected mice (<15 U/ml) before the 7th day of malaria infection . As can be seen in Fig. 1 , elevated serum IL6 levels were already seen in mice with early signs of neurological syndrome (i.e., isolated palsies, mild ataxia, referred to as "early CM") (n = 4) . The highest IL-6 serum levels were observed in mice with full-blown cerebral malaria, which occurs in 80-90% of PbA-infected mice (5) (hemi-or tetraplegia, convulsions, severe ataxia, tendency to roll over upon stimulation, and eventually coma, referred to as "CM") (n = 9) . Serum IL6 levels were also markedly elevated on day 7 of the nonlethal Plasmodium yoelii infection (n = 10), and gradually returned to normal by day 21, thus following a pattern very similar to the parasitemia in these animals (Fig. 2) .
Modulation of 11,6 by Anticytokine Antibodies . As can be seen on Fig. 3 , the rise in serum I1r6 concentrations was completely abolished in mice treated with antiTNF (seven mice tested, p < 0.001) or anti-IFN-y antibodies (eight mice tested, p < 0.001), whereas the combined treatment with anti-IL-3 and anti-GM-CSF antibodies, which totally prevents the rise of TNF (4), only partially (although significantly p = 0.02) reduced the 11,6 production in infected mice (nine mice tested) .
Effects ofAnti-IL6 Antibody Treatment. 20 CBA/Ca mice were infected with PbA and 10 were injected intraperitoneally on days 0 and 4 with 0.2 ml of 6114 mAb or medium as control. In anti-II,6 mAb-treated infected mice, IL-6 was not detected in the serum at day 7 or 8 of infection (<15 U/ml, 9 mice tested) . However, anti-IIT6 mAb failed to prevent ECM, which developed in 8 of 10 mice, as in 8 of 10 infected untreated mice. Anti-II,6 mAb treatment significantly reduced the malaria-associated rise in serum IgG as detected on day 7 of infection (Table 1) , but had no effect on IgM levels . Treatment of PbA-infected mice with another rat mAb (anti-IFN--y) did not affect serum IgG levels (Table 1) . In contrast to total IgG, serum-specific antimalarial antibody levels were not affected by anti-IL6 mAb treatment (221 .4 ± 46 .2 OD units by ELISA and 2,478 .6 ± 1,505 .8 titration units by immunofluorescence) compared to 165 .3 ± 45 .7 OD units and 2,041 ± 1,745 .5 in control infected mice. In this paper we show that IL-6 is produced in considerable amounts during blood stage infection by malaria parasites, and that this cytokine may be involved in hypergammaglobulinemia rather than in the pathogenesis of the cerebral complications . Our results also indicate that malaria-induced 11,6 production depends upon other cytokines, since it can be modulated by anticytokine antibodies administered in vivo. At least one signal for IL-6 production is provided by TNF, as shown on brain macrophages or astrocytes in vitro (16), since antiTNF antibody treatment prevents the rise of IL6 in serum of plasmodium-infected mice, in agreement with experiments in Escherichia coli LPS-injected baboons (16) . The rise in malarial-induced serum IL6 was abolished by anti-IFN-y antibody but only partially prevented by the dual treatment with anti-IL3 and anti-GM-CSF antibodies. In other models, both IIr1 (9) and IFN-,y (11) also have a role in IIr6 production . Several infectious diseases have been already reported to induce IL6 (17) (18) (19) (20) . In the context of malaria, 11,6 has been found in mice after sporozoite infection (21) and in man with severe falciparum infection (22) . IL6, at least in vitro, can be produced by brain cells (16, 23) , in addition to the three cell types involved in ECM.
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While 11,6 is induced by TNF (10, 11), two arguments do not support major role of 11,6 in the pathogenesis of ECM . 
Time after
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Results are given as mean t SEM. ' The levels of Ig in treated and control animals were compared with nonparametric Mann-Whitney test (ND, not determined; NS, not significant) .
First, the dissociation between high levels of IL-6 and occurrence of ECM (in CBA/Ca mice treated by anti-IL3 and anti-GM-CSF or in mice infected with the non lethal P. )velii parasite) . Second, the absence of protective effect of in vivo treatment with anti-IL6 mAb on the development of ECM. In addition, unlike TNF (24, 25) Grau et al .
Brief Definitive Report prevents hypergammaglobulinemia without reducing the specific antimalarial humoral response, one has to hypothesize that cytokines other than 1176 (such as IL-2 and IL,4) are more instrumental in specific antibody responses. IL6 is thus possibly involved in malarial complications associated with hypergammaglobulinemia . In addition, overexpression of 11,6 has been suggested in the development of B cell lymphomas (27) . IL6 production might contribute to the higher frequency of Burkitt's lymphomas associated with plasmodium infections in epidemiological studies (28) . The significance of IL-6 production in malaria may thus go beyond the cerebral syndrome. 
